A randomized phase II study of everolimus in combination with chemoradiation in newly diagnosed glioblastoma: results of NRG Oncology RTOG 0913 Article

keywords

  • CANCER
  • INHIBITION
  • Neurosciences & Neurology
  • Oncology
  • PTEN-DEFICIENT
  • RAD001
  • RADIATION-THERAPY
  • RAPAMYCIN
  • SIGNALING PATHWAY
  • TEMOZOLOMIDE
  • everolimus
  • glioblastoma
  • mTOR inhibition
  • radiation sensitizer

Digital Object Identifier (DOI)

start page

  • 666

end page

  • 673

issue

  • 5